$GNBT This is HUGE NEWS on Thursday
Generex Provides Coronavirus Update: Generex Receives Contract from Chinese Partners to Develop a COVID-19 Vaccine Using Ii-Key Peptide Vaccines
Terms approved to proceed with collaborative effort with international consortium
MIRAMAR, Fla., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company has received a contract from the China Technology Exchange, Beijing Zhonghua Investment Fund Management Co., LTD., Biology Institute of Shandong Academy of Sciences and Sinotek-Advocates International Industry Development (Shenzhen) Co., LTD. The terms of the contract, which have been agreed to in writing by both parties, include an upfront payment of $1 million to initiate the project work in the United States, a $5 million licensing fee for the Ii-Key technology, payment by the Chinese consortium for all costs and expenses related to the development of a COVID-19 vaccine, and a 20% royalty on each dose of vaccine produced.
Joe Moscato, President & Chief Executive Officer of Generex has signed the draft contract with deal terms and will be traveling to China next week to sign the final, official contract with its Chinese partners to develop a COVID-19 vaccine using the Ii-Key immune system activation technology. Generex management will be presenting the company’s data, demonstrating the technology, and finalizing work plans with those partners to produce an Ii-Key-COVID-19 peptide vaccine that can be tested in human studies within 90 days. Mr. Moscato is expected to sign the official agreements on behalf of Generex at a signing ceremony in China next week, at which time Generex will make further announcements.
Mr. Moscato said, “Our subsidiary NuGenerex Immuno-Oncology has developed Ii-Key peptide vaccines against several potentially pandemic viruses, including bird flu, swine, flu, HIV, and a previous coronavirus, SARS. This wealth of experience has enabled us to develop a standardized protocol for rapid vaccine development, so we are positioned to respond in the event of a new, emerging pathogen. Our partners in China have recognized the power of our Ii-Key platform and have delivered this contract to establish a collaboration to combat the COVID-19 epidemic, and we are excited to begin the work.”
Generex Biotechnology Investing DD 2020
1) The CEO Joe Moscato is a marketing guy and he knows how to get everyone to see the big picture and to take long term views. Even if it means taking less pay now for rewards later. Including himself. No big fat salary for Joe now. In fact he has pretty much deferred any salary. What CEO does that?
2) GNBT filed an S-1 registration with the SEC with the future plans all noted. When the S-1 gets approved they have financing approved for a minimum of $40M to be used if needed. Think of it as a line of credit. The S-1 could be approved ANY day.
3) The financing allows them to purchase a majority interest privately held company named Altucell who may have a treatment which may cure Type 1 Diabetes. This companies research is fairly advanced and additional trials are about ready to go once funding arrives. Why?
from Generex:
"as part of our due diligence
process, we pinpointed specific, comparable deals that validate the huge value of the
ALTuCELL acquisition, as evidenced by the recently announced purchase of Semma
Therapeutics by Vertex Pharmaceuticals for close to a billion dollars."
4) Generex is spinning off NGIO and it should be trading on the Nazdaq within a few weeks. It will be owned by Generex shareholders as we have been awarded dividend shares and ~70% by Generex. NGIO has the coronavirus vaccine to develop and a vaccine it is currently studying for breast cancer. Prostate research is underway as well. Other research is pending the new funding. Regarding number 4, I should have mentioned Merck. No doubt you all know about Keytruda being huge in cancer. The Generex/NGIO breast cancer study is a combo of NGIO's AE37 and Merck's Keytruda.
5) One of Generex's subs has a number of test kits for various ailments is working on a coronavirus test kit NOW.
6) Another sub, Olaregen has a wound care product being sold in the VA system and producing significant NEW revenue for Generex as of the last 3 months.
7) It was just announced two of the other subs have had a 400% increse in sales of their medical products recently
Over the next few day I will tell you about the MSO, HMO,Type 2 diabetes treatment and more.
Count yourselves lucky to be here now just before the good stuff is going to come together. Flippers will look back and regret having sold quite soon.
Did I mention Generex has already filed for UPLISTING ON THE NAZDAQ for GNBT? Waiting on the S-1 to be approved and the financing to be put to work.
Generex Provides Coronavirus Update: Generex Receives Contract from Chinese Partners to Develop a COVID-19 Vaccine Using Ii-Key Peptide Vaccines
Terms approved to proceed with collaborative effort with international consortium
MIRAMAR, Fla., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company has received a contract from the China Technology Exchange, Beijing Zhonghua Investment Fund Management Co., LTD., Biology Institute of Shandong Academy of Sciences and Sinotek-Advocates International Industry Development (Shenzhen) Co., LTD. The terms of the contract, which have been agreed to in writing by both parties, include an upfront payment of $1 million to initiate the project work in the United States, a $5 million licensing fee for the Ii-Key technology, payment by the Chinese consortium for all costs and expenses related to the development of a COVID-19 vaccine, and a 20% royalty on each dose of vaccine produced.
Joe Moscato, President & Chief Executive Officer of Generex has signed the draft contract with deal terms and will be traveling to China next week to sign the final, official contract with its Chinese partners to develop a COVID-19 vaccine using the Ii-Key immune system activation technology. Generex management will be presenting the company’s data, demonstrating the technology, and finalizing work plans with those partners to produce an Ii-Key-COVID-19 peptide vaccine that can be tested in human studies within 90 days. Mr. Moscato is expected to sign the official agreements on behalf of Generex at a signing ceremony in China next week, at which time Generex will make further announcements.
Mr. Moscato said, “Our subsidiary NuGenerex Immuno-Oncology has developed Ii-Key peptide vaccines against several potentially pandemic viruses, including bird flu, swine, flu, HIV, and a previous coronavirus, SARS. This wealth of experience has enabled us to develop a standardized protocol for rapid vaccine development, so we are positioned to respond in the event of a new, emerging pathogen. Our partners in China have recognized the power of our Ii-Key platform and have delivered this contract to establish a collaboration to combat the COVID-19 epidemic, and we are excited to begin the work.”
Generex Biotechnology Investing DD 2020
1) The CEO Joe Moscato is a marketing guy and he knows how to get everyone to see the big picture and to take long term views. Even if it means taking less pay now for rewards later. Including himself. No big fat salary for Joe now. In fact he has pretty much deferred any salary. What CEO does that?
2) GNBT filed an S-1 registration with the SEC with the future plans all noted. When the S-1 gets approved they have financing approved for a minimum of $40M to be used if needed. Think of it as a line of credit. The S-1 could be approved ANY day.
3) The financing allows them to purchase a majority interest privately held company named Altucell who may have a treatment which may cure Type 1 Diabetes. This companies research is fairly advanced and additional trials are about ready to go once funding arrives. Why?
from Generex:
"as part of our due diligence
process, we pinpointed specific, comparable deals that validate the huge value of the
ALTuCELL acquisition, as evidenced by the recently announced purchase of Semma
Therapeutics by Vertex Pharmaceuticals for close to a billion dollars."
4) Generex is spinning off NGIO and it should be trading on the Nazdaq within a few weeks. It will be owned by Generex shareholders as we have been awarded dividend shares and ~70% by Generex. NGIO has the coronavirus vaccine to develop and a vaccine it is currently studying for breast cancer. Prostate research is underway as well. Other research is pending the new funding. Regarding number 4, I should have mentioned Merck. No doubt you all know about Keytruda being huge in cancer. The Generex/NGIO breast cancer study is a combo of NGIO's AE37 and Merck's Keytruda.
5) One of Generex's subs has a number of test kits for various ailments is working on a coronavirus test kit NOW.
6) Another sub, Olaregen has a wound care product being sold in the VA system and producing significant NEW revenue for Generex as of the last 3 months.
7) It was just announced two of the other subs have had a 400% increse in sales of their medical products recently
Over the next few day I will tell you about the MSO, HMO,Type 2 diabetes treatment and more.
Count yourselves lucky to be here now just before the good stuff is going to come together. Flippers will look back and regret having sold quite soon.
Did I mention Generex has already filed for UPLISTING ON THE NAZDAQ for GNBT? Waiting on the S-1 to be approved and the financing to be put to work.
